Medifast, Inc. (MED)
| Market Cap | 124.06M -14.7% |
| Revenue (ttm) | 346.10M -36.3% |
| Net Income | -20.02M |
| EPS | -1.82 |
| Shares Out | 10.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 103,715 |
| Open | 12.35 |
| Previous Close | 12.27 |
| Day's Range | 12.03 - 12.40 |
| 52-Week Range | 9.22 - 15.46 |
| Beta | 0.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 4, 2026 |
About MED
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, essential amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND,... [Read more]
Financial Performance
Financial StatementsNews
Medifast names Nicholas Johnson as CEO
Medifast (MED) “announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will…
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson w...
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than t...
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024) Early weight loss at week four is a strong predictor of clinically relevant outc...
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
The global weight loss industry was valued at $16.3 billion in 2025, yet peer-reviewed clinical validation of program outcomes remains uneven across the category Randomized controlled trials control f...
Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
Body composition, specifically visceral fat levels and lean mass, plays a meaningful role in long-term metabolic health (Serra MC, et al., 2019) Structured plans, habit building, and dedicated coach s...
Medifast Earnings Call Transcript: Q1 2026
Sequential revenue growth returned for the first time in three years, driven by a 19% year-over-year increase in coach productivity and strong referral activity, despite a 34% revenue decline and ongoing disruption from GLP-1 medications. Profitability improvements are targeted for Q4 2026, with a new product launch and cost savings expected to support future growth.
Medifast Earnings release: Q1 2026
Medifast released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Medifast Slides: Q1 2026
Medifast has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Medifast Quarterly report: Q1 2026
Medifast has published its Q1 2026 quarterly earnings report on May 4, 2026.
Medifast sees Q2 EPS ($1.00)-(50c), one estimate (43c)
Sees Q2 revenue $60M-$80M, one estimate $74.7M
Medifast sees FY26 EPS ($2.75)-($1.55), one estimate ($1.98)
Sees FY26 revenue $270M-$300M, one estimate $273.7M
Medifast reports Q1 EPS (19c), one estimate (52c)
Reports Q1 revenue $76.0M, one estimate $69.2M. “We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of…
Medifast Announces First Quarter 2026 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter en...
Medifast Proxy statement: Proxy filing
Medifast filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter...
Medifast Proxy statement: Proxy filing
Medifast filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Medifast Proxy statement: Proxy filing
Medifast filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Medifast announces cooperation agreement with Steamboat Capital
Medifast (MED) announced the company’s board of directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners as independent director candidates to stand for election at…
Medifast Announces Cooperation Agreement with Steamboat Capital
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Di...
Medifast announces Optavia available for HSA, FSA reimbursement
Medifast (MED) announced that Optavia’s metabolic health system is now available for reimbursement on select insurance plans using Health Savings Accounts and Flexible Spending Accounts. “This is a ma...
Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients
BALTIMORE--(BUSINESS WIRE)--As part of its continued focus on improving metabolic health, Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for re...
Medifast price target lowered to $12 from $15 at Stephens
Stephens lowered the firm’s price target on Medifast (MED) to $12 from $15 and keeps an Equal Weight rating on the shares. While the firm believes that operating discipline and…
Medifast Earnings Call Transcript: Q4 2025
Q4 2025 saw revenue drop 36.9% year-over-year due to a smaller coach base, but coach productivity rose 6%, marking the first positive trend since 2022. The company is transitioning to a metabolic health focus, expects new product launches in late 2026, and targets profitability improvements starting Q4 2026.
Medifast Annual report: Q4 2025
Medifast has published its Q4 2025 annual report on February 17, 2026.